STOCK TITAN

IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

IGM Biosciences, a clinical-stage biotechnology company, announced that CEO Fred Schwarzer will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 5:15 p.m. PST in San Francisco. The event will be available via a live webcast on the company's website, with a replay accessible for 30 days.

The company focuses on developing IgM antibodies for treating cancer, infectious diseases, and autoimmune disorders, leveraging a collaboration with Sanofi to develop IgM antibody agonists.

Positive
  • None.
Negative
  • None.

MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PST in San Francisco.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.

About IGM Biosciences, Inc.
IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, infectious diseases and autoimmune and inflammatory diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and immunology and inflammation targets. For more information, please visit www.igmbio.com.

Contact
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com


FAQ

What is the date and time of IGM Biosciences' presentation at the J.P. Morgan Healthcare Conference?

IGM Biosciences' presentation is scheduled for January 10, 2023, at 5:15 p.m. PST.

Where can I watch the live webcast of IGM Biosciences' presentation?

The live webcast will be available on the 'Events and Presentations' page in the 'Investors' section of IGM Biosciences' website.

How long will the replay of the IGM Biosciences presentation be available?

The replay of the presentation will be archived on the IGM Biosciences website for 30 days.

What is the focus of IGM Biosciences as a biotechnology company?

IGM Biosciences focuses on developing IgM antibodies for treating cancer, infectious diseases, and autoimmune disorders.

Who is collaborating with IGM Biosciences in their research efforts?

IGM Biosciences has an exclusive collaboration agreement with Sanofi to develop IgM antibody agonists.

IGM Biosciences, Inc.

NASDAQ:IGMS

IGMS Rankings

IGMS Latest News

IGMS Stock Data

416.25M
21.74M
35.05%
63.99%
4.78%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MOUNTAIN VIEW